394 related articles for article (PubMed ID: 16651809)
1. Targets of cytoprotection in acute ischemic stroke: present and future.
Lizasoain I; Cárdenas A; Hurtado O; Romera C; Mallolas J; Lorenzo P; Castillo J; Moro MA
Cerebrovasc Dis; 2006; 21 Suppl 2():1-8. PubMed ID: 16651809
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport.
Hurtado O; Moro MA; Cárdenas A; Sánchez V; Fernández-Tomé P; Leza JC; Lorenzo P; Secades JJ; Lozano R; Dávalos A; Castillo J; Lizasoain I
Neurobiol Dis; 2005 Mar; 18(2):336-45. PubMed ID: 15686962
[TBL] [Abstract][Full Text] [Related]
3. Delayed post-ischemic administration of CDP-choline increases EAAT2 association to lipid rafts and affords neuroprotection in experimental stroke.
Hurtado O; Pradillo JM; Fernández-López D; Morales JR; Sobrino T; Castillo J; Alborch E; Moro MA; Lizasoain I
Neurobiol Dis; 2008 Jan; 29(1):123-31. PubMed ID: 17884513
[TBL] [Abstract][Full Text] [Related]
4. Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection.
Romera C; Hurtado O; Mallolas J; Pereira MP; Morales JR; Romera A; Serena J; Vivancos J; Nombela F; Lorenzo P; Lizasoain I; Moro MA
J Cereb Blood Flow Metab; 2007 Jul; 27(7):1327-38. PubMed ID: 17213861
[TBL] [Abstract][Full Text] [Related]
5. Gene expression in cerebral ischemia: a new approach for neuroprotection.
Millán M; Arenillas J
Cerebrovasc Dis; 2006; 21 Suppl 2():30-7. PubMed ID: 16651812
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of iNOS activity by 1400W decreases glutamate release and ameliorates stroke outcome after experimental ischemia.
Pérez-Asensio FJ; Hurtado O; Burguete MC; Moro MA; Salom JB; Lizasoain I; Torregrosa G; Leza JC; Alborch E; Castillo J; Knowles RG; Lorenzo P
Neurobiol Dis; 2005 Mar; 18(2):375-84. PubMed ID: 15686966
[TBL] [Abstract][Full Text] [Related]
7. Deterioration in acute ischemic stroke as the target for neuroprotection.
Serena J; Rodríguez-Yáñez M; Castellanos M
Cerebrovasc Dis; 2006; 21 Suppl 2():80-8. PubMed ID: 16651818
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis and neuroprotection in cerebral ischemia.
Gutiérrez M; Díez Tejedor E; Alonso de Leciñana M; Fuentes B; Carceller F; Roda JM
Cerebrovasc Dis; 2006; 21 Suppl 2():118-26. PubMed ID: 16651822
[TBL] [Abstract][Full Text] [Related]
9. Ischemic preconditioning: a novel target for neuroprotective therapy.
Blanco M; Lizasoain I; Sobrino T; Vivancos J; Castillo J
Cerebrovasc Dis; 2006; 21 Suppl 2():38-47. PubMed ID: 16651813
[TBL] [Abstract][Full Text] [Related]
10. Oxaloacetate: a novel neuroprotective for acute ischemic stroke.
Campos F; Sobrino T; Ramos-Cabrer P; Castillo J
Int J Biochem Cell Biol; 2012 Feb; 44(2):262-5. PubMed ID: 22085530
[TBL] [Abstract][Full Text] [Related]
11. Neuroprotective therapy.
Hickenbottom SL; Grotta J
Semin Neurol; 1998; 18(4):485-92. PubMed ID: 9932619
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evaluation of glutamate transporter 1 (GLT-1) mediated neuroprotection following cerebral ischemia/reperfusion injury.
Verma R; Mishra V; Sasmal D; Raghubir R
Eur J Pharmacol; 2010 Jul; 638(1-3):65-71. PubMed ID: 20423712
[TBL] [Abstract][Full Text] [Related]
13. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.
Rothstein JD; Patel S; Regan MR; Haenggeli C; Huang YH; Bergles DE; Jin L; Dykes Hoberg M; Vidensky S; Chung DS; Toan SV; Bruijn LI; Su ZZ; Gupta P; Fisher PB
Nature; 2005 Jan; 433(7021):73-7. PubMed ID: 15635412
[TBL] [Abstract][Full Text] [Related]
14. [Neuroprotection by aspirin in cerebrovascular pathology].
Lorenzo Fernández P
An R Acad Nac Med (Madr); 2002; 119(2):311-20; discussion 320-6. PubMed ID: 12518657
[TBL] [Abstract][Full Text] [Related]
15. Opioids modulate post-ischemic progression in a rat model of stroke.
Kao TK; Ou YC; Liao SL; Chen WY; Wang CC; Chen SY; Chiang AN; Chen CJ
Neurochem Int; 2008 May; 52(6):1256-65. PubMed ID: 18294735
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotection by rosiglitazone in transient focal cerebral ischemia might not be mediated by glutamate transporter-1.
Verma R; Mishra V; Gupta K; Sasmal D; Raghubir R
J Neurosci Res; 2011 Nov; 89(11):1849-58. PubMed ID: 21826699
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological Induction of Ischemic Tolerance by Glutamate Transporter-1 (EAAT2) Upregulation.
Chu K; Lee ST; Sinn DI; Ko SY; Kim EH; Kim JM; Kim SJ; Park DK; Jung KH; Song EC; Lee SK; Kim M; Roh JK
Stroke; 2007 Jan; 38(1):177-82. PubMed ID: 17122424
[TBL] [Abstract][Full Text] [Related]
18. For ischemic brain damage, is preclinical evidence of neuroprotection by presynaptic blockade of glutamate release enough?
Nava-Ocampo AA; Reyes-Pérez H; Bello-Ramírez AM; Mansilla-Olivares A; Ponce-Monter H
Med Hypotheses; 2000 Jan; 54(1):77-9. PubMed ID: 10790730
[TBL] [Abstract][Full Text] [Related]
19. Up-regulation of brain-enriched miR-107 promotes excitatory neurotoxicity through down-regulation of glutamate transporter-1 expression following ischaemic stroke.
Yang ZB; Zhang Z; Li TB; Lou Z; Li SY; Yang H; Yang J; Luo XJ; Peng J
Clin Sci (Lond); 2014 Dec; 127(12):679-89. PubMed ID: 24943094
[TBL] [Abstract][Full Text] [Related]
20. Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra.
Castellanos M; Sobrino T; Castillo J
Cerebrovasc Dis; 2006; 21 Suppl 2():71-9. PubMed ID: 16651817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
